Getting a GLP-1 covered: prior authorization, appeals and your options

Why GLP-1 coverage is complicated

Each brand is approved for specific uses, and plans cover by approved use. Ozempic and Mounjaro are approved for type 2 diabetes, which nearly every plan covers in some form. Wegovy, Zepbound and Foundayo are approved for weight management, which many plans exclude or cover only if an employer pays extra for it; Wegovy is also approved to lower heart attack and stroke risk in people with heart disease, and Zepbound for obstructive sleep apnea in adults with obesity, and those approvals can open coverage where weight management alone would not.

Prescribing a diabetes brand for weight loss alone is legal for a prescriber, but plans generally deny it, and pharmacies may question it, because the plan pays for the approved diabetes use. The cleanest route is a prescription for the brand approved for your condition.

Find out exactly what your plan covers

Before the prescription is written, look up the drug in your plan’s formulary, the list of covered drugs, which is usually on the insurer’s website or in the member portal. Note whether it is covered, which tier it is on, and whether it carries prior authorization, step therapy or quantity limits. If weight-management drugs are not listed at all, ask the plan whether they are excluded; for coverage through work, ask your employer’s benefits team, since self-funded employer plans decide their own exclusions.

Ask for the plan’s written criteria for approval. They commonly follow the FDA labels: for weight management, a body mass index of 30 or more, or 27 or more with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or sleep apnea, alongside diet and activity. Many plans also ask for documented prior attempts at weight loss, and for renewal they often require a minimum amount of weight lost by a set point.

How prior authorization works

Prior authorization means the plan approves the drug before it pays. The prescriber’s office submits a request with your diagnosis, your measurements, relevant conditions and lab results, and the treatments you have tried. Approvals are often time-limited, so put the renewal date in your calendar and ask the office to start the renewal early, with your progress documented.

• Your current weight, height and body mass index, with dates.
• Weight-related conditions, such as high blood pressure, prediabetes or diabetes, high cholesterol, sleep apnea or heart disease.
• Prior weight-loss efforts, including programs, diet changes and medicines tried.
• For diabetes, recent A1c results and the diabetes medicines tried.
• For a sleep apnea or heart indication, the sleep study or the cardiac diagnosis.

What to do after a denial

Read the denial letter carefully: it must state the reason and how to appeal. Many denials are about missing information rather than eligibility, and resubmitting with the missing documents can be enough. If not, your prescriber can ask for a peer-to-peer review, a conversation with the plan’s reviewing clinician, which often resolves borderline cases.

You also have the right to a formal internal appeal, with a letter of medical necessity from your prescriber explaining why the drug is needed and why covered alternatives are not suitable. If the plan upholds the denial, most plans must then allow an independent external review by a reviewer outside the insurer. A plan exclusion, as opposed to a medical-necessity denial, is harder to overturn, because the drug was never covered; then the conversation is with your employer about adding the benefit, or about the paying options below.

Medicare and Medicaid

Federal law excludes drugs used only for weight loss from Medicare Part D, but Part D plans cover GLP-1 medicines for type 2 diabetes, and can cover Wegovy to lower cardiovascular risk in people with heart disease and Zepbound for obstructive sleep apnea, usually with prior authorization. From July 2026 to the end of 2027, the Medicare GLP-1 bridge program lets eligible Part D enrollees get certain obesity GLP-1 medicines for a flat monthly copay. Part D coverage determinations follow set deadlines, faster when waiting could seriously harm your health, and appeals can go to independent review.

Medicaid coverage of weight-management GLP-1s varies by state, and some states have added or dropped it as budgets changed; diabetes coverage is standard. Check your state Medicaid plan’s preferred drug list.

If the answer is still no

Several routes remain. Novo Nordisk sells Wegovy and Ozempic directly to self-paying patients through NovoCare, and Eli Lilly sells Zepbound and Foundayo through LillyDirect, at prices set by dose that are usually far below what a pharmacy charges for the brand in cash; the TrumpRx website links to the same offers. Generic liraglutide, the older daily GLP-1, is available from many manufacturers, and its cash price varies between pharmacies, which is where comparing quotes makes the most difference. Money in a health savings account or flexible spending account can pay for a GLP-1 prescribed to treat obesity or diabetes.

Avoid unverified online sellers. Since the shortages ended, compounded copies are allowed only in narrow circumstances, and products sold without a prescription or as research chemicals are neither legal nor safe.

Staying covered over time

Coverage is rarely permanent. Plans change formularies each year, employers revisit weight-management benefits, and renewals depend on documented progress. Keep a record of your weight, measurements and lab results, check your plan’s formulary before each open enrollment, and ask your prescriber to start renewals early. If your plan changes, a switch to another covered GLP-1 is sometimes possible, but doses are not directly equivalent, so the prescriber chooses the new starting dose.